Kidney, Phase II

A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact David A. Braun

david.braun@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

David A. Braun, MD, PhD
Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar

Sub-Investigators

Last Updated
12/12/2024
Study HIC
#2000035939